The Ordinary’s new serum claims to address signs of ageing with ‘growth factors’ – but does it work?
The skincare disruptor’s latest launch is no exception: a growth factor face serum that addresses multiple visible signs of ...
bovnews29m
The Unexpected Biotech Breakthrough Everyone’s Talking About: Hoth Therapeutics (HOTH)
While Hoth Therapeutics has always been an up-and-comer in the world of biotech, the spotlight is now firmly on them due to the CLEER-001 trial, where early results from the HT-001 treatment are ...
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
Pharmabiz13h
Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma
Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma: Tokyo Tuesday, January 7, 2025, 09:00 Hrs [IST] Astellas ...
HUTCHMED's Combination Therapy For Lung Cancer Granted Priority Review By NMPA
Limited (HUTCHMED) (HCM) announced that the New Drug Application (NDA) for the combination of ORPATHYS(savolitinib) ...